title: Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.
abstract: Abnormalities of chromosome 16 in AML include del(16q), inv(16) and t(16;16). These three groups have been categorized together and have been associated with high complete remission (CR) and survival rates following Ara-C-based chemotherapy. We have reviewed the 63 AML or MDS patients with an abnormality of chromosome 16 treated at MD Anderson Cancer Center (MDACC) over the past 18 years. Marked differences in survival and remission duration (RD) were noted between the inv(16) or t(16;16) patients and those with del(16q), whose outcome was no better than other M4 AML or MDS patients treated during the same period. Other differences characterizing del(16q) included a lack of CNS relapses, lower incidences of eosinophilia and M4 FAB subtype. Half the inv(16) patients had additional karyotypic abnormalities. The overall survival and remission duration for those patients were no different from those for patients with inv(16) alone, although the probability of remaining in first CR at 2 years was higher in the inv(16) alone group. There was no difference in overall survival for the 45 patients who received HDAC vs those who did not. The incidence of CNS relapse was, however, markedly reduced for the HDAC patients. Eosinophilia did not correlate with improved survival. We conclude that del(16q) confers a different prognosis from inv(16) and t(16;16) and for the purposes of prognostication or treatment recommendations should no longer be categorized with them. Additional karyotypic changes however, which accompany inv(16) in 50% of cases do not influence the overall outcome compared to patients with inv(16) alone.
authors.affiliation: Department of Hematology, MD Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: P
authors.initials: P
authors.lastname: Marlton
authors.forename: M
authors.initials: M
authors.lastname: Keating
authors.forename: H
authors.initials: H
authors.lastname: Kantarjian
authors.forename: S
authors.initials: S
authors.lastname: Pierce
authors.forename: S
authors.initials: S
authors.lastname: O'Brien
authors.forename: E J
authors.initials: EJ
authors.lastname: Freireich
authors.forename: E
authors.initials: E
authors.lastname: Estey
mesh_terms: D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000235:genetics; D007446:Chromosome Inversion; D002874:Chromosome Mapping; D002885:Chromosomes, Human, Pair 16; D003561:Cytarabine / Q000627:therapeutic use; D003582:Cytogenetics; D006801:Humans; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000145:classification / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D011237:Predictive Value of Tests; D011379:Prognosis; D017384:Sequence Deletion; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine